🔗 Share this article

Given that the United States proceeds with unprecedented changes to its immunization recommendations, an unexpected name has surfaced somewhat surprisingly: Høeg, a Danish American sports physician and public health researcher who first made her name by questioning COVID-19 vaccinations during the global health crisis and has zeroed in on alleged fatalities after Covid vaccination in her brief position at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Immunization Program

Agency leaders had intended to announce radical revisions to the childhood immunization program earlier this month, aligning the US with the Danish immunization schedule, sources say – a major change that would place the US at odds with many the global community with little proof for public health gain. The announcement has been delayed until the next year.

In place of Vinay Prasad, Tracy Beth Høeg is listed to address the audience at the meeting. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the office this year.

A Shift at the Regulatory Body

The acting appointment may indicate a strengthened alliance between the pharmaceutical and biologics centers as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it points to a renewed priority upon rolling back long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for halting specific childhood immunization guidelines in the US in order to be more like Denmark's approach, a society with universal health coverage and a population roughly the size of the state of Wisconsin.

So far public appearances, she has kept her attention on immunizations – typically the responsibility of Prasad, director of the FDA’s vaccine center – rather than drug regulation.

Doubts Over Qualifications

The appointee has little discernible track record in drug development, approval processes or leadership, which has been typical for former leaders of the biologics center. She has worked at the FDA as a key advisor to the FDA chief and the vaccine center since spring.

“It seems she lacks to have the necessary background” for running the CDER, stated a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She has no expertise in managing a sizeable institution. She has no expertise in pharmaceutical oversight.”

Past commissioners of the center would “be deeply familiar with laws and regulations and the science of medication creation”, commented Janet Woodcock. “Clearly, she doesn’t have the type of experience that prior appointees who ran CBER have had.”

The drug center has an enormous range of responsibilities at the agency, Woodcock pointed out.

“Many people just focuses on the innovative therapies, but the off-patent medication office clears thousands of generic medications. There’s a biosimilars division, over-the-counter program and other areas, and all of those need to be looked after,” Woodcock explained. “The area you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

There is also, a significant administrative aspect to the job, which supervises over 5,000 employees. “It is a massive administrative position, if you perform it correctly,” the former official said.

Response and Disputed Policies

In response to questions about Høeg’s qualifications and whether this selection represents greater collaboration among regulatory chiefs on immunizations, a press secretary said that the “inquiries stem from flawed premises”.

“Her resume is consistent with the responsibilities of her job,” the representative stated, citing the months Høeg spent guiding the agency head on “drug safety and regulatory science, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s controversial expedited review system, a contentious one-day drug-approval program that apparently troubled her preceding directors. “How are these drugs being picked for this fast-track system? Who takes the decisions?” Howard said. “There’s a lot of lack of transparency going on at the regulatory body right now.”

In general, he said, “the FDA appears to be shifting towards less stringent regulations of all drugs, with the exception of vaccines.”

Established Past Work on Vaccines

Regarding immunizations, Dr. Høeg has a more established, if troubling, history, Howard observe. She released a analysis using unconfirmed volunteer-provided data to estimate the rate of heart inflammation following COVID-19 immunization. She counseled the Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccines are riskier than they are.

Part of her “desired changes” for the new administration encompassed revising regulations for new vaccines and ending “unnecessary” vaccines, she stated post-election on a online show. At the FDA, Dr. Høeg has reportedly floated the idea of barring teenage boys from receiving COVID-19 vaccines.

“She is an all-around dogmatist who starts off with her preconceived notions and works backwards to retrofit the evidence in a very deceptive, dishonest way,” Dr. Howard said.

Taking Control and a “Campaign of Retribution”

Høeg joined other skeptics, {like|